Nintedanib Accordpharma (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby reducing fibroblast proliferation, new blood‑vessel formation, and extracellular matrix production. This dual antifibrotic and anti‑angiogenic activity helps limit lung scarring and tumor growth.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nintedanib in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both slow disease progression, Nintedanib targets a broader range of tyrosine kinases, which may provide additional benefit in certain patients, whereas pirfenidone’s safety profile is characterized by different gastrointestinal and skin reactions.

Nintedanib tablets should be stored at temperatures below 25 °C, in their original blister pack, protected from moisture and direct light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

The medication is taken orally as a whole tablet, usually with food to lessen gastrointestinal upset. Patients should swallow the tablet with a full glass of water and avoid crushing or chewing it, unless otherwise directed by a healthcare professional.

Serious adverse events include significant liver enzyme elevations, bleeding complications, cardiovascular events such as myocardial infarction, severe infections, gastrointestinal perforations, and rare but severe skin reactions. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment, known hypersensitivity to the drug, and in pregnant or breastfeeding women. Caution is also advised for individuals with active bleeding disorders, uncontrolled cardiovascular disease, or those taking strong CYP3A4 inhibitors without dose adjustment.